Means, Responders, and Meaning: Evaluation of Clinical Trials in Osteoarthritis

Arthritis and Rheumatism

Volumn 48, Issue 11, 2003, Pages 3001-3003

  Schnitzer, Thomas J ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; VALDECOXIB;

CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; MEDICAL DECISION MAKING; METHODOLOGY; OSTEOARTHRITIS; PAIN ASSESSMENT; PATIENT ATTITUDE; PATIENT SATISFACTION; PRIORITY JOURNAL; SAMPLE SIZE; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 0242410532     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11329     Document Type: Editorial

References (17)

1. Gibofsky A, Williams GW, McKenna F, Fort JG. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum 2003;48: 3102-11.
2. Felson DT, Anderson JJ. A review of evidence on the discriminant validity of outcome measures in rheumatoid arthritis. J Rheumatol 2001;28:422-6.
3. Bellamy N, Carr A, Dougados M, Shea B, Wells G. Towards a definition of "difference" in osteoarthritis. J Rheumatol 2001;28: 427-30.
4. Kirwan JR. Minimum clinically important difference: the crock of gold at the end of the rainbow? J Rheumatol 2001;28:439-44.
5. Geba FP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002;287:64-71.
6. Dougados M, Leclaire P, van der Heijde D, Bloch DA, Bellamy N, Altman RD. Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage 2000;8: 395-403.
7. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
8. Towheed TE. Published meta-analyses of pharmacological therapies for osteoarthritis. Osteoarthritis Cartilage 2002;10:836-7.
9. Watson MC, Brookes ST, Kirwan JR, Faulkner A. Non-aspirin, non-steroidal anti-inflammatory drugs for treating osteoarthritis of the knee (Cochrane review). In: Cochran Library; Issue 3. Oxford: Update Software; 2003. Cochrane Database Syst Rev 2003;1.
10. Emery P, Kong SX, Ehrich EW, Watson DJ, Towheed TE. Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature review. Clin Ther 2002;24:1225-91.
11. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002;287:64-71.
12. Celecoxib [package insert]. New York: Pfizer Pharmaceuticals; 2002.
13. Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160:1781-7.
14. Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman M, et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. J Rheumatol 1999;26:2438-47.
15. Saag K, van der Heijde D, Fisher C, Samara A, DeTora L, Bolognese J, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Arch Fam Med 2000;9:1124-34.
16. Truitt KE, Sperling RS, Ettinger WH Jr, Greenwald M, DeTora L, Zeng Q, et al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging 2001;13: 112-21.
17. McKenna F, Weaver A, Fiechtner JJ, Bello AE, Fort JG. COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled randomized double-blind study. J Clin Rheumatol 2001;7:151-9.